<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237210</url>
  </required_header>
  <id_info>
    <org_study_id>0803M28421</org_study_id>
    <nct_id>NCT01237210</nct_id>
  </id_info>
  <brief_title>7T MRS in Parkinson's Disease</brief_title>
  <official_title>Magnetic Resonance Spectroscopy of Parkinson's Disease at 7 Tesla</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking for healthy controls and patients with Parkinson's (PD) to perform an&#xD;
      MR scan.&#xD;
&#xD;
        1. The neurochemical profile of the SN of patients with PD as measured by high field MRS&#xD;
           will differ from that of healthy controls, in that glutathione will be lower due to&#xD;
           oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis&#xD;
           markers myo-inositol and glutamine will be higher due to inflammation (glial activation)&#xD;
           and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage.&#xD;
&#xD;
        2. There will be a relationship between neurochemical changes and disease severity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic resonance spectroscopy (MRS)</measure>
    <time_frame>Baseline</time_frame>
    <description>We will utilize optimized magnetic resonance spectroscopy (MRS) methodology to address theories of pathogenesis of Parkinson's disease (PD) by quantifying glutathione (GSH), lactate, glutamine and myo-inositol levels of the unilateral substantia nigra (SN) of healthy volunteers and patients with PD.</description>
  </primary_outcome>
  <enrollment type="Actual">78</enrollment>
  <condition>Parkinson's Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's patients and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Parkinson's disease Group&#xD;
&#xD;
          -  Parkinson's disease (clinical diagnostic criteria)&#xD;
&#xD;
          -  Age 45-75 years inclusive&#xD;
&#xD;
          -  Able to safely undergo MRI scanning&#xD;
&#xD;
          -  Absence of diabetes and smoking&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
        Healthy Control Group&#xD;
&#xD;
          -  Age 45-75 years inclusive&#xD;
&#xD;
          -  Able to safely undergo MRI scanning&#xD;
&#xD;
          -  Absence of diabetes and smoking&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Parkinson's disease Group&#xD;
&#xD;
          -  Dementia (clinically determined by PI Dr. Tuite)&#xD;
&#xD;
          -  Diagnosis of atypical parkinsonism&#xD;
&#xD;
          -  Inability to safely undergo MRI scanning&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Unstable medical conditions&#xD;
&#xD;
          -  Present smoker&#xD;
&#xD;
          -  Diabetic (on oral or injectable medications for diabetes)&#xD;
&#xD;
          -  Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan&#xD;
&#xD;
          -  Does not meet age criteria&#xD;
&#xD;
        Healthy Control Group&#xD;
&#xD;
          -  Has a 1st degree relative with PD&#xD;
&#xD;
          -  Dementia (clinically determined by PI Dr. Tuite)&#xD;
&#xD;
          -  Inability to safely undergo MRI scanning&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Unstable medical conditions&#xD;
&#xD;
          -  Present smoker&#xD;
&#xD;
          -  Diabetic (on oral or injectable medications for diabetes)&#xD;
&#xD;
          -  Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan&#xD;
&#xD;
          -  Does not meet age criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Tuite, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota/CMRR</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>PD</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

